Device Trial Radar · NCT06453187
A Modified Platform Trial of Multiple CAMPs for the Management of Diabetic Foot Ulcers and Venous Leg Ulcers
Last checked: Nov 19, 2026Latest source record: Jul 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
350
Planned (sponsor's estimate)
Start
Nov 18, 2024
Primary completion
Dec 31, 2026
Study completion Mar 31, 2027
Sponsor
- Lead sponsor
- Integra LifeSciences CorporationPublic (IART)
- Sponsor type
- Industry
- Collaborators
- SerenaGroup, Inc.
- First posted
- Jun 11, 2024
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine how well multiple CAMPs (Cellular, Acellular and Matrix-Like Products) and Standard of Care work when compared to Standard of Care alone in achieving complete closure of hard-to-heal diabetic foot and venous leg ulcers.
Conditions
- Diabetic Foot Ulcer
- Venous Leg Ulcer
Interventions
Urinary Bladder Matrix (UBM) sheet device for Venous Leg UlcersDevice
Application of Urinary Bladder Matrix (UBM) sheet device, a porcine-derived extracellular matrix scaffold, and participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and offloading) until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
Urinary Bladder Matrix (UBM) sheet device for Diabetic Foot UlcersDevice
Application of Urinary Bladder Matrix (UBM) sheet device, a porcine-derived extracellular matrix scaffold, and participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and offloading) until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
AmnioExcel Plus for Venous Leg UlcersDevice
Application of AmnioExcel Plus, a tri-layer (amnion-chorion-amnion) dehydrated human placental membrane allograft, and participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and offloading) until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
AmnioExcel Plus for Diabetic Foot UlcersDevice
Application of AmnioExcel Plus, a tri-layer (amnion-chorion-amnion) dehydrated human placental membrane allograft, and participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and offloading) until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
Standard of CareProcedure
Participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and offloading) until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of complete wound closure for target ulcerTime frame: 1-12 weeks
Locations
13 sites in 1 country. Site status is shown where the registry gives one.
Angel City Research
Los Angeles, California
Center for Clinical Research
San Francisco, California
ILD Research Center
Vista, California
10 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.